Abstract
The increasing occurrence of antibiotic-resistant pathogens influences the treatment approach to respiratory tract infections and complicates the selection of the anti-infectious drug and dosing regimen. Pharmacokinetic (PK) and pharmacodynamic (PD) characteristics both influence dosing regimens of antimicrobials. PK (the overall disposition of the drug in the body) is reflected by the serum concentration profile over time. PD can be characterized by the susceptibility of the pathogen to the drug, determined by measuring the minimum inhibitory concentration (MIC), which is a potency of the drug. There is an increasing need to identify new therapeutic approaches which improve the chance to reduce the morbidity and obtain successful outcomes. So far, antibiotic dosing has been focused on PK concepts, mainly the penetration of drug into sites of infection and its elimination half-life. Recently, a new appealing approach integrating PK and PD features has been suggested to implement optimal antibiotic dosing regimens, since several studies in animals and humans found a striking correlation between bacteriological outcome and specific PK/PD indices. It appears it would lead to better results not only in terms of clinical and bacteriological cure but also in the whole patient care.
Keywords: Antibiotics, MIC, pharmacokinetic/pharmacodynamic indices, respiratory tract infection
Current Respiratory Medicine Reviews
Title: Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Volume: 2 Issue: 1
Author(s): D. Soy, J. R. Badia and A. Torres
Affiliation:
Keywords: Antibiotics, MIC, pharmacokinetic/pharmacodynamic indices, respiratory tract infection
Abstract: The increasing occurrence of antibiotic-resistant pathogens influences the treatment approach to respiratory tract infections and complicates the selection of the anti-infectious drug and dosing regimen. Pharmacokinetic (PK) and pharmacodynamic (PD) characteristics both influence dosing regimens of antimicrobials. PK (the overall disposition of the drug in the body) is reflected by the serum concentration profile over time. PD can be characterized by the susceptibility of the pathogen to the drug, determined by measuring the minimum inhibitory concentration (MIC), which is a potency of the drug. There is an increasing need to identify new therapeutic approaches which improve the chance to reduce the morbidity and obtain successful outcomes. So far, antibiotic dosing has been focused on PK concepts, mainly the penetration of drug into sites of infection and its elimination half-life. Recently, a new appealing approach integrating PK and PD features has been suggested to implement optimal antibiotic dosing regimens, since several studies in animals and humans found a striking correlation between bacteriological outcome and specific PK/PD indices. It appears it would lead to better results not only in terms of clinical and bacteriological cure but also in the whole patient care.
Export Options
About this article
Cite this article as:
Soy D., Badia R. J. and Torres A., Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era, Current Respiratory Medicine Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339806775486218
DOI https://dx.doi.org/10.2174/157339806775486218 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews Prevalence and Resistance Profiles of Vancomycin-resistant Enterococcal Isolates in Iran; An Eight-month Report from Nine Major Cities
Infectious Disorders - Drug Targets Nucleotide Second Messenger Signaling as a Target for the Control of Bacterial Biofilm Formation
Current Topics in Medicinal Chemistry Gene Cloning and Homology Modeling of the 3-Oxoacyl-ACP Synthase from Aeromonas hydrophila for Drug Discovery
Letters in Drug Design & Discovery Antibiotic Prophylaxis in Urologic Prosthetic Surgery
Current Pharmaceutical Design Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Prevalence of Dilated Cardiomyopathy in HIV-Infected African Patients Not Receiving HAART: A Multicenter, Observational, Prospective, Cohort Study in Rwanda
Current HIV Research Anti-Pathogenic Efficacy and Molecular Targets of a Polyherbal Wound- Care Formulation (Herboheal) Against Staphylococcus aureus
Infectious Disorders - Drug Targets Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Short Term Statin Treatment Improves Survival and Differentially Regulates Macrophage-Mediated Responses to Staphylococcus aureus
Current Pharmaceutical Biotechnology A Review of QSAR studies to Discover New Drug-like Compounds Actives Against Leishmaniasis and Trypanosomiasis
Current Topics in Medicinal Chemistry Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals Enterococcal Cytolysin: A Novel Two Component Peptide System that Serves as a Bacterial Defense Against Eukaryotic and Prokaryotic Cells
Current Protein & Peptide Science Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials